<DOC>
	<DOCNO>NCT00390143</DOCNO>
	<brief_summary>This study investigate long-term protection offer GSK Biologicals ' meningococcal vaccine 134612 3.5 year vaccination . Subjects vaccinate 15 19 year age . This extension phase start 18 month vaccination part subject vaccinate primary study enrol extension phase . No new subject enrol . This protocol post deal objective &amp; outcome measure extension phase 18 , 30 42 month vaccination . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT00126945 ) . The Protocol Posting update order comply FDA Amendment Act , September 2007 .</brief_summary>
	<brief_title>Study Adolescents/Adults Evaluate Persistence 3.5 Yrs GSK Biologicals Meningococcal Vaccine 134612</brief_title>
	<detailed_description>Subjects previously vaccinate 15 19 year age GSK Biologicals ' meningococcal vaccine 134612 Mencevax™ ACWY . This extension phase start 18 month vaccination part subject enrol extension phase . No additional vaccine administer study new subject enrol . The subject three blood sample take : 18 , 30 42 month vaccination .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parents/guardians comply requirement protocol . A male female , prim meningococcal vaccine 134612 Mencevax™ ACWY primary vaccination study 18 month first persistence assessment complete study . Written inform consent obtain subject/ parent guardian subject . Written inform assent obtain subject , applicable , time study entry . • Administration meningococcal polysaccharide meningococcal polysaccharide conjugate vaccine since last visit primary vaccination study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Persistence</keyword>
</DOC>